Skip to main content

Clinical Trials Using Filgrastim

Review the clinical trials studying filgrastim on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 27

Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Status: Active
Location: 167 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 144 locations
Brentuximab Vedotin in Early-Stage Hodgkin Lymphoma, RADAR Trial
Status: Active
Location: 5 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Decitabine in Combination with Filgrastim Post-Hematopoietic Stem Cell Transplant in Preventing Relapse of Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Related Myeloid Malignancies in Pediatric and Young Adult Patients
Status: Active
Location: 2 locations
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Entrectinib for the Treatment of Patients Less Than 3 Years of Age with NTRK1/2/3 or ROS1 Fused High Grade Glioma or Other Central Nervous System Tumor
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Venetoclax plus CLAG-M for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
PEEL-224 Alone and in Combination with Vincristine and Temozolomide for the Treatment of Refractory, Progressive, or Relapsed Childhood Solid Tumors, Neuroblastoma or Rhabdomyosarcoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Personalized Vaccine (TTRNA-DCs & TTRNA-xALT) for the Treatment of Adult Patients with Recurrent/Progressive WHO Grade 2 or 3 Oligodendroglioma, ADAGiO Trial
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination Chemotherapy with Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Genetically Engineered Cells (P140K MGMT Hematopoietic Stem Cells), O6-Benzylguanine, Temozolomide, and Carmustine for the Treatment of Resected Supratentorial Glioblastoma or Gliosarcoma
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Cytokine Induced Memory-like Natural Killer Cell Therapy after Donor Stem Cell Transplant in Treating Children and Young Adults with Relapsed Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri